(Q35120795)

English

A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial). (English)

1 reference

Europe PubMed Central

6 August 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

Wasaburo Koizumi

1

1 reference

Europe PubMed Central

6 August 2017

Satoshi Morita

2

1 reference

Europe PubMed Central

6 August 2017

Yuh Sakata

3

1 reference

Europe PubMed Central

6 August 2017

publication date

16 December 2014

1 reference

Europe PubMed Central

6 August 2017

Japanese Journal of Clinical Oncology

1 reference

Europe PubMed Central

6 August 2017

45

1 reference

Europe PubMed Central

6 August 2017

3

1 reference

Europe PubMed Central

6 August 2017

303-306

1 reference

Europe PubMed Central

6 August 2017

Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4340275

9 July 2018

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4340275

9 July 2018

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4340275

9 July 2018

Distribution of ADH2 and ALDH2 genotypes in different populations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4340275

9 July 2018

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU205

21 January 2018

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU205

21 January 2018

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU205

21 January 2018

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU205

21 January 2018

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4340275

27 September 2018

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4340275

27 September 2018

Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25516635

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/JJCO/HYU205

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35120795&oldid=1629151016"